Literature DB >> 15562828

Structural biology of insulin and IGF-1 receptors.

Pierre De Meyts1, Jane Palsgaard, Waseem Sajid, Anne-Mette Theede, Hassan Aladdin.   

Abstract

The insulin and IGF-1 receptors are members of the superfamily of receptor tyrosine kinases (RTKs). Many of these have been implicated in human cancers due to amplification, overexpression or somatic mutations of the gene. Congenital mutations of the RTKs are implicated in a growing number of inherited syndromes. Unlike most RTKs that are single-chain monomeric transmembrane polypeptides, the insulin and IGF-1 receptors are dimers made of two extracellular alpha subunits and two transmembrane beta subunits containing the tyrosine kinase domain. The alpha subunits contain the ligand binding sites, of which at least three subdomains have been mapped by photoaffinity cross-linking, alanine-scanning mutagenesis or minimized receptor constructs. All RTKs are dimeric or oligomeric in the ligand-activated form, a mechanism that allows for transphosphorylation of the kinase domains and triggers the signalling cascade. The residues of insulin involved in receptor binding have been mapped by alanine-scanning mutagenesis. They form at least two major epitopes that partially overlap with the dimer- and hexamer-forming surfaces of the insulin molecule, and we propose that insulin is using those surfaces to cross-link the receptor alpha subunits. This mechanism provides a structural basis for negative cooperativity in binding, and probably also operates in the IGF-receptor interaction.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15562828

Source DB:  PubMed          Journal:  Novartis Found Symp        ISSN: 1528-2511


  12 in total

1.  Structural resolution of a tandem hormone-binding element in the insulin receptor and its implications for design of peptide agonists.

Authors:  Brian J Smith; Kun Huang; Geoffrey Kong; Shu Jin Chan; Satoe Nakagawa; John G Menting; Shi-Quan Hu; Jonathan Whittaker; Donald F Steiner; Panayotis G Katsoyannis; Colin W Ward; Michael A Weiss; Michael C Lawrence
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-26       Impact factor: 11.205

Review 2.  The role of the insulin‑like growth factor (IGF) axis in osteogenic and odontogenic differentiation.

Authors:  H Al-Kharobi; R El-Gendy; D A Devine; J Beattie
Journal:  Cell Mol Life Sci       Date:  2014-04       Impact factor: 9.261

Review 3.  Cardiovascular effects of relaxin: from basic science to clinical therapy.

Authors:  Xiao-Jun Du; Ross A D Bathgate; Chrishan S Samuel; Anthony M Dart; Roger J Summers
Journal:  Nat Rev Cardiol       Date:  2009-11-24       Impact factor: 32.419

4.  Insulin-like growth factor 1 receptor signaling regulates skin development and inhibits skin keratinocyte differentiation.

Authors:  Marianna Sadagurski; Shoshana Yakar; Galina Weingarten; Martin Holzenberger; Christopher J Rhodes; Dirk Breitkreutz; Derek Leroith; Efrat Wertheimer
Journal:  Mol Cell Biol       Date:  2006-04       Impact factor: 4.272

5.  B cells from patients with Graves' disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis.

Authors:  Raymond S Douglas; Vibharavi Naik; Catherine J Hwang; Nikoo F Afifiyan; Andrew G Gianoukakis; Daniel Sand; Shweta Kamat; Terry J Smith
Journal:  J Immunol       Date:  2008-10-15       Impact factor: 5.422

6.  Expression study of GLUT4 translocation-related genes in a porcine pre-diabetic model.

Authors:  Thea Kristensen; Merete Fredholm; Susanna Cirera
Journal:  Mamm Genome       Date:  2015-09-07       Impact factor: 2.957

Review 7.  The metabolic and mitogenic properties of basal insulin analogues.

Authors:  Norbert Tennagels; Ulrich Werner
Journal:  Arch Physiol Biochem       Date:  2013-02       Impact factor: 4.076

Review 8.  Understanding the Key to Targeting the IGF Axis in Cancer: A Biomarker Assessment.

Authors:  Kunal Amratlal Lodhia; Piyawan Tienchaiananda; Paul Haluska
Journal:  Front Oncol       Date:  2015-07-08       Impact factor: 6.244

9.  Dual targeting of the insulin-like growth factor and collateral pathways in cancer: combating drug resistance.

Authors:  Joseph A Ludwig; Salah-Eddine Lamhamedi-Cherradi; Ho-Young Lee; Aung Naing; Robert Benjamin
Journal:  Cancers (Basel)       Date:  2011-07-26       Impact factor: 6.639

Review 10.  Insulin-Like Growth Factor Pathway and the Thyroid.

Authors:  Terry J Smith
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-04       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.